Fig. 1

A bispecific antibody (BsAb)-based culturing platform for one-step producing the prostate cancer-specific T cells. A Schematic of BsAb-based culturing platform, culture the human PBMCs with anti-PSMA/anti-CD3 BsAb and stimulated with IL-2, which can induce PBMCs proliferation and differentiation into CD3⁺ CD8⁺ T cells. During this cultivation process, the BsAb anti-CD3 end can bind to CD3⁺ T cell surface and cause the BsAb-armed T cells production. Moreover, the BsAb anti-cancer end allows BsAb-armed T cell to target cancer cells and activate CD3 downstream signaling to kill cancer cells specifically. B Four kinds of bispecific antibody structures were developed, namely anti-PSMA/anti-CD3 (Fab-scFv), anti-PSMA/anti-CD3(scFv-Fab), anti-PSMA/anti-CD3(scFv-scFv), and anti-PSMA/anti-CD3 (hole-knob). IgK leader, IgK leader sequence. IRES, internal ribosome entry site. 6His, six-histidine tag. Knob Fc, a human IgG1 heavy chain with knob mutations (S354C, T366W). Hole Fc, a human IgG1 heavy chain with hole mutations (D399K, E356K). C The function of each BsAb to recognize Jurkat, LNCaP, or 3T3. The results were analyzed by flow cytometry